Status:
COMPLETED
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Dohme Australia
Conditions:
AIDS
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.
Eligibility Criteria
Inclusion
- 18 or older, required lab results, currently taking no more than two of the proposed once daily arm medications with medications administered twice daily and women of child bearing potential.
Exclusion
- virological failure, serious medical condition, known toxicities to any of the once daily arm medications, lab abnormalities, women who are pregnant/breastfeeding
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00207168
Start Date
April 1 2004
End Date
December 1 2006
Last Update
April 22 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.